

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Hittinger et al.**

Examiner: Not yet known

Application No.: **10/773,806**

Art Unit: 1625

Filed: **February 6, 2004**

Title: **CHEMICAL DERIVATIVES AS ANTITELOMERASE AGENTS WHICH
BIND SPECIFICALLY TO THE G-QUADRUPLEX DNA STRUCTURES
AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT**

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

June 25, 2007

Date

sanofi-aventis US LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (610) 889-8995
Telefax (908) 231-2626
Sanofi-Aventis Docket No. FRAV2003/0004 US NP

Kelly L. Bender
Kelly L. Bender, Reg. No. 52,610
Attorney for Applicant